CGTLive®’s Weekly Rewind – August 2, 2024

News
Article

Review top news and interview highlights from the week ending August 2, 2024.

CGTLive®’s Weekly Rewind

CGTLive®’s Weekly Rewind

Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Pfizer Drops Development of DMD Gene Therapy Fordadistrogene Movaparvovec

The program’s cancellation follows a previous announcement that its phase 3 trial had missed its primary end point.

2. Joshua M. Hare, MD, on Promising Data on Lomecel-B for Alzheimer Disease

The cofounder and chief science officer of Longeveron discussed updated data from the phase 2a CLEAR MIND study.

3. New Study Recommends Shorter, Flexible Monitoring After CAR T-Cell Therapy

There were no new cases of CRS past 2 weeks after infusion and non-relapse mortality was driven by infection in follow-up.

4. Chris Wright, MD, PhD, on Anelloviruses, a Potential Alternative to AAV for Gene Therapy

The chief medical officer and head of translational research at Ring Therapeutics discussed research presented at ASGCT 2024.

5. Umoja Biopharma's In Situ CAR-T Therapy Cleared for US Trial in Hematologic Malignancies

The trial will be open to patients with relapsed/refractory large-B-cell lymphoma and chronic lymphocytic leukemia.

Recent Videos
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program in the Division of Hematology/Oncology at David Geffen School of Medicine at University of California, Los Angeles (UCLA)
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.